Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
ORKA
Oruka Therapeutics, Inc.
CAPPED RATING
Oruka Therapeutics, Inc. (ORKA) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Growth (D+).
Quantitative Factor Evaluation • Updated
Overall Rating
2.5
/ 5.0
C+
Value
C+
Factor Score
2.5
/ 5.0
Growth
D+
Factor Score
1.6
/ 5.0
Profitability
B-
Factor Score
2.9
/ 5.0
Momentum
B-
Factor Score
2.9
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-36.5
EV / EBITDA
-34.1
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-6.5%
Price Return 12M
272.3%
Catalyst Signal
0.00
Market Cap
$7.1B
TTM Revenue
N/A
Price / Sales
N/A
ROE
-18.1%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C+ (2.5) | D+ (1.6) | B- (2.9) | B- (2.9) | C+ (2.6) | C+ (2.5) |
| 2026-11-07 | C+ (2.5) | D (1.4) | B- (2.9) | B- (2.9) | C+ (2.7) | C (2.5) |
| 2026-10-31 | C+ (2.5) | D (1.4) | B- (2.9) | B- (3.1) | C+ (2.7) | C+ (2.5) |
| 2026-10-24 | C+ (2.5) | D (1.4) | B- (2.9) | B- (2.9) | C+ (2.6) | C (2.5) |
| 2026-10-17 | C+ (2.5) | D (1.4) | B- (2.9) | B- (3.1) | C+ (2.6) | C+ (2.5) |
Page
1
of
4